CYP2E1 and cancer: The pooled result failed to identified any significant associations between CYP2E1 Dra I polymorphism and the urinary cancer risk (CD + CC vs. DD, OR = 0.913, 95% CI = 0.791–1.051, P = 0.202; C vs. D, OR = 0.978, 95% CI = 0.847–1.117, P = 0.748).